Replies to post #501644 on Anavex Life Sciences Corp (AVXL)

[abew4me]

Excellent! But I'd like to know if the CHMP committee has been updated on all of these findings?

Does anyone know if there is an open-door line of communication that allows applicants to submit additional information to be considered?

[boi568]

I see on Stocktwits that Mayo gives the ABCLEAR3 30mg subgroup at 55-56 percent by measuring at 48 weeks rather than at the outset, which I calculated as ~47 percent.

I think you guys get the point.

Anavex is not Texas sharpshooting -- since they are not changing any trial endpoint numbers -- but I have to wonder, given the obvious fact that the response distribution graph must be bimodal and that these data will entirely populate one mode, whether the post hoc nature of the ABCLEAR3 analysis is all that statistically unsound. Wouldn't the possibility of this extreme special case as random be much more unlikely than a traditionally (i.e., Gaussian) random post hoc finding? Where are our stat guys?

[boi568]

The preprint of the genomic study is out with more details, including a stat sig absolute improvement in the self-reported Quality of Life secondary endpoint in the ABCLEAR3 30mg subgroup:

https://www.medrxiv.org/content/10.1101/2025.09.27.25336656v1

[chrismiss_everyday]

“This poster will be displayed at RFMASA 2025 from September 29 to October 1 in Lausanne, Switzerland. (That's why the commentary on the linked pdf is in French).”

Probably cause for attendees to go ‘Oui! Oui! Oui!’ all the way home. 🤌